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 Progress in treatment and diagnosis of yaws: hope for 
eradication?
Endemic treponematoses are a group of chronic 
bacterial infections caused by non-cultivable, spiral-
shaped bacteria closely related to Treponema pallidum 
pallidum—the syphilis agent.1 Yaws is the most common 
of the endemic treponematoses and is prevalent in poor 
rural communities in remote tropical areas of Africa, 
Asia, and the Paciﬁ c Islands.1–3 The infection typically 
aﬀ ects children and adolescents and is transmitted 
through skin-to-skin contact with an active lesion. 
Without treatment, about 10% of people infected with 
Treponema pallidum pertenue—the yaws agent—develop 
disﬁ guring and disabling complications. Prevention 
of yaws is based on interruption of transmission by 
early diagnosis and treatment of individual cases and 
mass or targeted treatment of aﬀ ected communities. 
Diagnosis of yaws is based mainly on clinical observation 
and epidemiological ﬁ ndings. However, because yaws 
can be confused with other diseases that are present in 
the tropics, diagnosis must be conﬁ rmed by laboratory 
techniques.3–5
Yaws was one of the ﬁ rst diseases targeted by WHO 
for eradication—ie, permanent reduction to zero of 
yaws prevalence on a worldwide scale. The Global 
Yaws Control Program ran from 1952 to 1964, treated 
50 million individuals, and reduced the prevalence of 
yaws by more than 95%.3 Unfortunately, the disease 
re-emerged in the late 1970s after control eﬀ orts 
waned. In March, 2012, WHO convened a meeting in 
Morges, Switzerland, to develop a new strategy for 
eradication of yaws by 2020. The Morges strategy6 
is based on initial mass treatment of endemic 
communities followed by resurveys every 6 months to 
detect and treat remaining cases.
Although the task of yaws eradication is daunting, 
two advances have rekindled hope for success. First, 
the longstanding WHO-recommended treatment for 
yaws is one intramuscular injection of benzathine 
benzylpenicillin (1·2 million units for adults and 
0·6 million units for children). Although eﬀ ective, use 
of penicillin has many associated issues—eg, the need 
for refrigeration and for trained personnel to administer 
the drug, the risk of blood-borne pathogen transmission 
via needles, and the potential for anaphylaxis. In 2012, 
Mitjà and colleagues reported that one oral dose of 
azithromycin (30 mg/kg, to a maximum of 2 g) was as 
eﬀ ective as benzathine benzylpenicillin for treatment 
of yaws-infected children in Papua New Guinea.7 
Azithromycin has several advantages, including safety 
and ease of administration.7 If ﬁ ndings of WHO-funded 
pilot studies conﬁ rm the eﬃ  cacy of azithromycin for 
yaws, its use as the preferred treatment would greatly 
simplify the task of community-based mass treatment.
Second, because of the antigenic similarity of the yaws 
and syphilis agents, serological tests for syphilis are also 
used for diagnosis of yaws, although these tests cannot 
diﬀ erentiate the two diseases.1,2,5 For serodiagnosis 
of active yaws infection, detection of antibodies to 
both non-treponemal (ie, cardiolipin) and treponemal 
components is needed. During the initial stage of 
yaws infection, non-treponemal serological tests for 
syphilis—such as the rapid plasma reagin (RPR) test—
become reactive, but after treatment they usually show 
greatly decreased reactivity or become non-reactive. 
By contrast, treponemal serological tests for syphilis—
such as the T pallidum haemagglutination assay 
(TPHA)—generally remain reactive for life, irrespective 
of treatment, precluding the ability to distinguish 
between active and past infections. Although RPR 
reactivity is a better indicator of active infection and the 
need for treatment, a serum sample is needed for the 
RPR test, and the test must be done in a clinical setting, 
which is rarely available in yaws-endemic areas.
In The Lancet Global Health, Telek Ayove and 
colleagues8 report a comparison of the Dual Path 
Platform (DPP) Syphilis Screen and Conﬁ rm test 
(Chembio Diagnostic Systems, Medford, NY, USA) 
with non-treponemal (RPR) and treponemal (TPHA) 
serological tests for diagnosis of yaws in two remote 
communities in Papua New Guinea with a high 
prevalence of the infection. The DPP point-of-care test 
detects treponemal (T1) and non-treponemal (T2) 
antibodies simultaneously.9 When compared with TPHA, 
the DPP T1 test had a sensitivity of 88·4% and speciﬁ city 
of 95·2%. By comparison with the RPR test, the DPP T2 
test had a sensitivity of 87·9% and speciﬁ city of 92·5%. 
However, sensitivity of the DPP T2 test rose to 94·1% 
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for specimens with higher quantitative RPR titres—
ie, 1:8 or higher. Furthermore, the combined results 
of the DPP T1 and T2 tests had a sensitivity of 93·9%, 
compared with the combined results of reactive TPHA 
and high-titre RPR, which together are judged indicative 
of true yaws infection. The key value of the DPP test 
resides in the non-treponemal T2 part, which provides 
rapid and accurate results for ﬁ eld diagnosis of active 
untreated yaws infection with only ﬁ nger-stick blood. 
Moreover, T2 optical density measurements taken 
before and after treatment (assessed with an automatic 
reader) fell progressively after treatment, showing a 
response comparable with that of quantitative RPR 
titres and, thus, possibly providing a way to monitor the 
eﬀ ectiveness of treatment.
Although advances in the treatment and diagnosis 
of yaws should substantially help eradication eﬀ orts, 
several uncertainties related to the biology and 
epidemio logy of the disease merit consideration, 
because they could impede eradication. First, the 
availability of a vaccine and the absence of a non-human 
reservoir were key factors for smallpox eradication. 
However, no vaccine is available for yaws and non-
human primates might be a reservoir for the disease.10 
Second, because of the scarcity of adequate surveillance 
data, the true burden and distribution of yaws is 
currently unknown.3 Third, although azithromycin 
is eﬀ ective for treatment of yaws, resistance could 
emerge to this macrolide antibiotic, which has been 
reported for the syphilis agent.11,12 Fourth, although the 
DPP test worked well for diagnosis of yaws in a setting 
of high prevalence, the positive predictive value of the 
DPP T2 test will diminish when the prevalence of yaws 
falls to very low levels, leading to false-positive results 
and the need for a more speciﬁ c test to ensure that 
transmission has been interrupted.8 Fifth, limited access 
to mobile populations in remote, sometimes dangerous, 
areas is a logistical diﬃ  culty that must be overcome to 
prevent reintroduction of yaws to treated communities.3
Despite the many hurdles, yaws eradication remains 
a worthwhile goal that, if successful, would prevent the 
suﬀ ering of thousands of people, particularly children, 
who are most aﬀ ected by this neglected tropical disease. 
The recent elimination of yaws in India,13 which was the 
result of an intensive government-backed programme, 
along with these advances in treatment and diagnosis, 
rekindle the hope that yaws eradication could be possible, 
as long as suﬃ  cient resources and strong political 
commitment are available for the very long term.
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